VJHemOnc is committed to improving our service to you

ASH 2019 | The Moffit experience of lenalidomide and rituximab for MCL

VJHemOnc is committed to improving our service to you

Bijal Shah

Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, outlines the Moffitt experience of lenalidomide plus rituximab in TP53-mutated mantle cell lymphoma (MCL) outside of the clinical trial setting. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter